The development of alpine tourism and the increasing trend towards adventure travel have made high mountain regions accessible not only to healthy people, but also to patients with cardiorespiratory diseases such as COPD. However, they are also more susceptible to altitude-related illnesses. Swiss doctors investigated whether prophylactic treatment with acetazolamide (AZA) changes the physical performance of COPD patients at high altitudes.
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Focus on prevention
Colorectal cancer screening – an update
- COPD therapy
Drug therapy – Update 2025
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Chronic and acute coronary syndrome